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Abstract
Background: The EU-AIMS Longitudinal European Autism Project (LEAP) is to date the largest multi-centre, multi-
disciplinary observational study on biomarkers for autism spectrum disorder (ASD). The current paper describes the
clinical characteristics of the LEAP cohort and examines age, sex and IQ differences in ASD core symptoms and
common co-occurring psychiatric symptoms. A companion paper describes the overall design and experimental
protocol and outlines the strategy to identify stratification biomarkers.
Methods: From six research centres in four European countries, we recruited 437 children and adults with ASD and
300 controls between the ages of 6 and 30 years with IQs varying between 50 and 148. We conducted in-depth
clinical characterisation including a wide range of observational, interview and questionnaire measures of the ASD
phenotype, as well as co-occurring psychiatric symptoms.
Results: The cohort showed heterogeneity in ASD symptom presentation, with only minimal to moderate site differences
on core clinical and cognitive measures. On both parent-report interview and questionnaire measures, ASD
symptom severity was lower in adults compared to children and adolescents. The precise pattern of differences varied
across measures, but there was some evidence of both lower social symptoms and lower repetitive behaviour severity in
adults. Males had higher ASD symptom scores than females on clinician-rated and parent interview diagnostic measures
but not on parent-reported dimensional measures of ASD symptoms. In contrast, self-reported ASD symptom severity was
higher in adults compared to adolescents, and in adult females compared to males. Higher scores on ASD symptom
measures were moderately associated with lower IQ. Both inattentive and hyperactive/impulsive ADHD symptoms were
lower in adults than in children and adolescents, and males with ASD had higher levels of inattentive and hyperactive/
impulsive ADHD symptoms than females.
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Conclusions: The established phenotypic heterogeneity in ASD is well captured in the LEAP cohort. Variation both in
core ASD symptom severity and in commonly co-occurring psychiatric symptoms were systematically associated with sex,
age and IQ. The pattern of ASD symptom differences with age and sex also varied by whether these were clinician ratings
or parent- or self-reported which has important implications for establishing stratification biomarkers and for
their potential use as outcome measures in clinical trials.
Keywords: Autism, Autism spectrum disorder, Phenotype, Behaviours, Heterogeneity, Sex, Age, IQ
Background
Heterogeneity is a core feature of the ASD phenotype
Autism spectrum disorder (ASD) is a common neurode-
velopmental disorder, affecting ~1% of children and
adults [1–4]. The core characteristics are impairments in
social communication abilities, the presence of rigid,
repetitive and stereotyped behaviours, and atypical
sensory responses (DSM-5; [5]). However, there is wide
heterogeneity in clinical presentation, both in terms of
symptom profiles and severity (hence the use of the term
‘spectrum’; [6]) and levels of intellectual and functional
communication ability. Commonly associated conditions
range from psychiatric symptoms, such as anxiety disor-
ders and attention-deficit/hyperactivity disorder (ADHD)
[7] to medical conditions including epilepsy and gastro-
intestinal abnormalities [8]. Heterogeneity is present
both between individuals who fulfil the diagnostic cri-
teria and within individuals across development [9, 10].
Decomposing this heterogeneity may get us closer to
more precise inferences about which subsets of individ-
uals are best characterised by different cognitive theories
of ASD [11]. Wide variability is also present at the level
of aetiological mechanisms. Common genetic variants of
small effect size are thought to accumulate and contrib-
ute towards enhanced risk, implicating a diverse range
of biological pathways. Similarly, some rare genetic vari-
ants found in a small percentage of individuals are
highly penetrant for ASD (i.e. copy number variants, sin-
gle nucleotide variants) but also affect a diverse set of
biological pathways [12–14]. Thus, the genomic land-
scape of risk mechanisms is highly diverse. Environmen-
tal factors as well as the interplay between genetic and
environmental risk mechanisms are also likely import-
ant, though the magnitude of impact is still largely
unknown [15].
Heterogeneity within ASD is a challenge for basic
science attempts to understand the pathophysiological
and neurodevelopmental mechanisms that lead to the
disorder and for the development of effective psycho-
pharmacological or behavioural treatments [16]. Decom-
posing heterogeneity across individuals and at multiple
levels of analysis requires ‘big data’ approaches that are
both ‘broad’ (i.e. large numbers of people) and ‘deep’, i.e.
multiple levels of analysis within an individual—genetic
and cellular architecture, brain structure and function,
cognitive, behavioural, and clinical variation, assessing
individuals across development, etc. [17].
Variation of the ASD phenotype by sex, age and
intellectual ability
ASD is at least three times more prevalent in males than
females, and biological sex may be an important source
of heterogeneity in ASD presentation. Lai and colleagues
[18] recently summarised research on sex differences in
ASD, covering potential mechanisms underlying the sex
differential liability to possible sex differences in brain
structure and function. Other factors may also affect the
recognition and presentation of ASD symptoms in males
and females, including potentially different patterns or
profiles of symptoms and ‘compensatory’ or ‘masking’ of
symptoms in females [18]. In addition, there is evidence
from population studies that girls with similar levels of
symptoms to boys are less likely to be diagnosed by
community services [19], unless there are more substan-
tial behavioural or cognitive difficulties [20]. In terms of
clinical profile and behaviour, findings have been incon-
sistent. While a meta-analysis suggested lower levels of
repetitive and restricted behaviours and interests (RRB)
in females but comparable levels of social communica-
tion difficulties in males and females [19, 21], other
studies have reported greater social communication diffi-
culties and lower cognitive ability and adaptive function
in females [22, 23]. Similarly, some studies have reported
higher levels of anxiety in girls than boys with ASD and
more externalising symptoms in boys [24–26]—but
other studies have not [7]. Comparisons across studies
are compromised by differences between samples such
as varying rates of intellectual disability.
Age is another potential source of heterogeneity in
individuals with ASD. There are some reports of reduc-
tions in ASD symptoms over early childhood [27] but
also high variability in the trajectory over childhood and
into early adolescence with some children showing
stable high or low severity across development, while a
minority significantly improve or worsen, respectively
[28–33]. Several longitudinal studies have reported a
reduction in ASD symptoms in adulthood, although
functional outcomes for many individuals remain poor
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[34–36]. A number of longitudinal studies have reported
lower levels of psychiatric symptoms in adolescence than
in childhood [37, 38], and others have reported further
reductions into adulthood [39] and even throughout the
adult life course [40].
Variation in intellectual ability is included in DSM-5
as a ‘clinical specifier’, indicating its importance in driv-
ing heterogeneity of ASD. In many samples, lower IQ
has been modestly but significantly associated with
higher levels of ASD symptom severity [41, 42]. In con-
trast to the moderate association found in the general
population between low IQ and increased levels of exter-
nalising disorders [43, 44], some studies have reported
that in population-derived samples, this association was
only present in adolescents (and not children) with ASD
[7, 38]. A meta-analysis focusing on anxiety disorders in
ASD revealed complex associations with IQ, finding that
social anxiety was more common in studies with lower
IQ samples but that obsessive-compulsive disorder and
separation anxiety were higher in studies with higher IQ
samples [45].
Clinical characterisation of the EU-AIMS LEAP cohort
As described in the companion paper [46], as part of the
EU-AIMS clinical research programme [47–49], we
established the Longitudinal European Autism Project
(LEAP). Here, we report on the baseline clinical assess-
ment of the EU-AIMS LEAP cohort. The paper will first
describe the cohort and its clinical characteristics. Then,
taking advantage of the size and heterogeneity of the
cohort, we will examine whether there are sex, age and
IQ differences on measures of core ASD symptoms and
levels of commonly co-occurring psychiatric symptoms.
Methods
Participants
In this multi-site study, participants were recruited
between January 2014 and March 2017 across six
European specialist ASD centres: Institute of Psych-
iatry, Psychology and Neuroscience, King’s College
London (IoPPN/KCL, UK), Autism Research Centre,
University of Cambridge (UCAM, UK), University
Medical Centre Utrecht (UMCU, Netherlands), Rad-
boud University Nijmegen Medical Centre (RUNMC,
Netherlands), Central Institute of Mental Health
(CIMH, Germany) and the University Campus Bio-
Medico (UCBM) in Rome, Italy (see Table 1 for recruit-
ment information by site). In addition, twins discordant
for ASD were recruited at Karolinska Institutet, Swe-
den—however, twins were not included in the case-
control comparisons reported below. Participants were
recruited from a variety of sources including existing
volunteer databases, existing research cohorts, clinical
referrals from local outpatient centres, special needs
schools, mainstream schools and local communities.
Based on parent- or self-reported ethnicity, most partici-
pants were Caucasian white (73%). The remaining partici-
pants were described as either of mixed race (6%), Asian
(2%), black (1%) or other (2%). For 16% of participants
information on ethnicity was either not provided (12%) or
missing (4%). Annual household income was measured on
an 8-point-scale ranging from <£25,000 to >£150,000,
with the median annual household income being esti-
mated at £30,000–£39,999. Highest household parental
education was coded on a 5-point scale ranging from pri-
mary education to postgraduate qualifications; 61% of
households had at least one parent with education beyond
a high school diploma (i.e. with an undergraduate degree
from university). At each site, an independent ethics com-
mittee approved the study. All participants (where appro-
priate) and their parent/legal guardian provided written
informed consent.
Inclusion/exclusion criteria
Participant inclusion criteria for the ASD sample were
an existing clinical diagnosis of ASD according to DSM-
IV [50], DSM-IV-TR [51], DSM-5 [5] or ICD-10 [52]
criteria and age between 6 and 30 years. ASD diagnoses
were based on a comprehensive assessment of the
participant’s clinical history and/or current symptom
profile, depending on when the participant was originally
identified at that site. In addition, we assessed ASD
symptoms using the Autism Diagnostic Observation
Schedule (ADOS; [53, 54]) and the Autism Diagnostic
Interview-Revised (ADI-R; [55]). However, individuals
with a clinical ASD diagnosis who did not reach cut-offs
on these instruments were not excluded. Clinical judge-
ment has been found to be more stable than scores on
individual diagnostic instruments alone [56], reflecting
the moderate-to-good but still imperfect accuracy of
such tools [57].
Exclusion criteria included significant hearing or visual
impairments not corrected by glasses or hearing aids, a
history of alcohol and/or substance abuse or dependence
in the past year and the presence of any MRI contraindi-
cations (e.g. metal implants, braces, claustrophobia) or
failure to give informed written consent to MRI scan-
ning (or to provide contact details for a primary care
physician at centres where this is a pre-condition for
scanning). Participants were purposively sampled to
enable in depth experimental characterisation of poten-
tial biomarkers (including MRI scans). Therefore, we
excluded individuals with low IQ (<50) as core measures
(e.g. most cognitive tasks and MRI scanning without
sedation) were deemed difficult to administer in this
group. Participants who did not complete an IQ assess-
ment were excluded (controls: n = 7, ASD: n = 10). In the
TD group, individuals who had a T score of 70 or higher
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on the self-report (1 adult) or parent-report form (1 ado-
lescent, 3 children) of the Social Responsiveness Scale
[58] were also excluded.
In the ASD sample, psychiatric conditions (except for
psychosis or bipolar disorder) were allowed as up to 70%
of people with ASD have one or more psychiatric disor-
ders [7] and reflect DSM-5 that allows co-occurring
psychiatric disorders alongside an ASD diagnosis [5].
In future individual biomarker analyses, additional ex-
clusion criteria or sub-grouping may then be applied
(e.g. ADI-R cut-offs, medication-free, etc.).
Exclusion criteria of the TD/ID group were the same
as described above for the ASD participants with the
exception that in the TD group parent- or (where appro-
priate) self-report of a psychiatric disorder was also an
exclusion criteria.
Study schedules
Participants were split into four study schedules
depending on their age and cognitive ability level.
Three schedules included individuals with IQ in the
typical range (≥75) (children: aged 6–11 years, adoles-
cents: aged 12–17 years and adults: aged 18–30 years).
At two sites (KCL, RUNMC)1, adolescents and adults
(aged 12–30 years) with ASD and mild intellectual
disabilities (mild ID; defined by IQ between 50 and
742) were also recruited alongside age- and IQ-
matched individuals without ASD (mild ID group).
Each schedule received a tailored and largely compar-
able study protocol to take into account differences in
age and cognitive level [46]. Within each age band
(children, adolescents, adults), participants were re-
cruited with a similar male:female ratio (3:1) and IQ
composition so that predicted cognitive/biological dif-
ferences can be compared across sex and develop-
mental stages. Likelihood ratio tests confirmed that
the targeted male:female ratio did not differ signifi-
cantly across schedules (x2(2) = 1.41, p = .494) and
study sites (x2(5) = 2.69, p = .754), as well as between
ASD and TD groups within each age band (all p > .1).
Clinical measures—ASD symptomatology
Given the cautious conclusions of recent reviews of ASD
symptom measures as potential endpoints for clinical
trials [59–61], we used a range of different measures of
ASD symptoms (a full list of all clinical measures is
reported in the Additional file 1: Table 3). These various
ASD symptom measures have complementary strengths
and limitations, relevant to our clinical and conceptual
understanding of measurement of ASD symptomatology
[57]. The parent-report ADI-R algorithm gives histor-
ical/early developmental symptom severity; the ADOS is
an observational measure of current symptom severity.
Both are diagnostic instruments. The ADOS has a stan-
dardised ‘calibrated severity score’, that is equivalent
across different modules while the ADI-R produces raw
algorithm scores in the three core ASD behavioural
domains but is more susceptible to skew. The ADI and
ADOS were not administered to the typically developing
controls or mild ID cases without ASD. In addition,
dimensional measures of ASD symptomatology were
derived from a variety of questionnaires (described below).
Each of these questionnaires was parent rated and/or self
rated depending on age and cognitive level (see Table 2 for
a summary of parent-report and participant self-report
questionnaires). The use of both parent and self-report in
a subsample will allow us to determine if the pattern of
age and sex differences in ASD and associated psychiatric
symptoms varies by respondent, which will have implica-
tions both for mapping putative biomarkers onto the ASD
phenotype and for their use as outcomes in clinical trials.
The Social Responsiveness Scale, Second Edition (SRS-2;
[58]) is a parent-reported symptom questionnaire suitable
across the whole age range (and is sex normed) that in
addition has a self-report companion measure suitable for
adolescents and adults. Other questionnaire measures
(Autism Spectrum Quotient (AQ; [62–64]); Children’s
Social Behaviour Questionnaire (CSBQ; [65])/Adult Social
Behaviour Questionnaire (ASBQ; [66]) are designed as
more dimensional/trait measures of ASD severity and
have different versions across the age span. The inclusion
of multiple dimensional measures of ASD symptom
Table 1 Number of participants recruited by each site according to schedule and diagnostic group
Total Adults Adolescents Children Mild ID
ASD TD/ID ASD TD ASD TD ASD TD ASD ID
London (KCL) 159 89 55 38 41 19 32 14 31 18
Cambridge (UCAM) 59 34 17 14 22 10 17 10 3 0
Mannheim (CIMH) 36 38 7 5 20 25 7 8 2 0
Nijmegen (RUNMC) 117 74 24 13 31 28 32 22 30 11
Rome (UCBM) 22 19 21 19 0 0 0 0 1 0
Utrecht (UMCU) 44 46 18 20 12 12 13 14 1 0
Total 437 300 142 109 126 94 101 68 68 29
ASD autism spectrum disorder, TD typically developing, Mild ID intellectual disability
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severity will allow us to test which measure best
relates to neurobiological or neurocognitive bio-
markers and is most sensitive to change over time.
Other questionnaires measure aspects of the ASD
phenotype not well captured by the SRS-2, including
atypical sensory responses (Short Sensory Profile (SSP;
[67]) and repetitive, rigid and stereotyped behaviours
(Repetitive Behavior Scale-Revised (RBS-R; [68]).
The Autism Diagnostic Observation Schedule (ADOS;
[53, 54]), a standardised social interaction observation
assessment, was used to assess current symptoms in
ASD participants (module 2 for 2 participants, module 3
for 154 participants, module 4 for 208 participants).
Calibrated Severity Scores (CSS) for Social Affect (SA),
Restricted and Repetitive Behaviours (RRB) and Overall
Total were computed [69, 70], which provide standardised
autism severity measures that account for differences in
the modules administered. The Autism Diagnostic
Interview-Revised (ADI-R; [55]), a structured parent inter-
view, was completed with parents/carers of ASD partici-
pants. Standard algorithm scores which combine current
and historical symptom information were computed for
Reciprocal Social Interaction (Social), Communication,
and Restricted, Repetitive and Stereotyped Behaviours and
Interests (RRB). Current ADI-R scores were available on a
subset of the ASD sample (356/414 (86%)) but are not
reported in the current paper. Where ADOS and ADI-R
scores from previous assessments were available (ADOS:
within the past 12 months for children/past 18 months for
all other schedules; ADI-R: at any historical point since we
report the 4 to 5 years/ever algorithm scores), these
assessments were not repeated.
The Social Responsiveness Scale, Second Edition
(SRS-2; [58]) is a quantitative measure comprising 65
items asking about characteristic autistic behaviour
over the previous 6 months. Each item is scored
using a ‘0’ (not true) to ‘3’ (almost always true) on a
Likert scale. The total raw score is transformed into
sex-specific T scores, and here, we report both raw
and sex-standardised scores. Parent report was used
for all participants with ASD and mild ID, as well as
children and adolescents with typical development.
Adults with ASD additionally completed the self-
report form. Adults with typical development only
completed the self-report form as, for feasibility
reasons, in this schedule, parents were not enrolled in
the study.
The Repetitive Behavior Scale-Revised (RBS-R; [68])
assesses restricted repetitive behaviours associated
with ASD. Parents or caregivers rate 43 behaviours
(e.g. ‘arranges certain objects in a particular pattern
or place’; ‘need for things to be even or symmetrical’)
on a scale of 0–3, where 0 indicates the behaviour
does not occur and 3 indicates the behaviour does
occur and is a severe problem.
Sensory processing atypicalities were measured using
the SSP [67]. This parent-report questionnaire comprises
37 items, where each item is scored on a 5-point Likert-
rating scale from 1 (always occurs) to 5 (never occurs).
The SSP is based on the sensory profile [71]. Lower
scores on the SSP are indicative of greater impairment.
The CSBQ [65] is a 49-item parent-report question-
naire that is specifically useful in assessing behaviour
atypicalities across the entire ASD spectrum. Adults
received the ASBQ for either self or parent report, com-
posed of 44 items [66].
The AQ [62–64]) is a continuous self- or parent-
report measure that quantifies the degree to which
children, adolescents or adults of average intelligence
show behavioural characteristics associated with ASD.
Table 2 Summary of parent-report and participant self-report questionnaires
Phenotypic measures Adults (TD) Adults (ASD) Adolescents (TD/ASD) Children (TD/ASD) Mild ID (ID/ASD)
Dimensional measures of ASD symptoms
Social Responsiveness Scale-2nd Edition (SRS-2), S S & P S & P P P
Children’s Social Behaviour Questionnaire (CSBQ) - - P P P
Adults’ Social Behaviour Questionnaire (ASBQ) S S & P - - P (>18 years)
Autism Spectrum Quotient (AQ)—adult version S S & P - - -
Autism Spectrum Quotient (AQ)—adolescent version - - P - -
Autism Spectrum Quotient (AQ)—child version - - - P P
Repetitive Behaviour Scale-Revised (RBS-R) - P P P P
Short Sensory Profile (SSP) - P P P P
Psychiatric symptoms
DSM-5 ADHD rating scale S S & P P P P
Beck Anxiety Inventory S S S P P
Beck Depression Inventory S S S P P
S self-report (completed by participant), P parent-report (completed by primary carer or parent of participant), S & P self- and parent-report administered; - not administered
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The AQ consists of 50 statements asking about habits
and personal preferences. Each statement is rated by the
participant or parent/carer on a 4-point Likert-rating
scale from ‘definitely agree’, ‘slightly agree’, ‘slightly
disagree’ to ‘definitely disagree’. While adult participants
completed the AQ by self-report, the adolescent version
is parent report but is otherwise composed of the same
items compared to the adult AQ. The AQ-Child also
entails parent-report, yet items that were not age appro-
priate in the adolescent/adult questionnaire were revised
accordingly.
Intellectual ability
Level of intellectual abilities was assessed using the
Wechsler Abbreviated Scales of Intelligence—Second
Edition, WASI-II [72] or—in countries where the WASI
is not translated (i.e. The Netherlands, Germany and
Italy)—the four-subtest short forms of the German,
Dutch or Italian WISC-III/IV [73, 74] for children or
WAIS-III/IV [75, 76] for adults. The shortened versions
were used for feasibility reasons to not further prolong
the testing sessions for participants. All versions
included two verbal subscales (vocabulary, similarities)
and two non-verbal subscales (block design, matrix rea-
soning). To standardise data across sites, IQ was pro-
rated from two verbal subtests (vocabulary and
similarities) and two performance subtests (matrix rea-
soning and block design) using an algorithm developed
by [77] that produces an estimated IQ score that is
highly correlated (r = .93) with a full-Scale IQ obtained
by administering the complete test. Age-appropriate
national population norms were available for each partici-
pating site, and these were used to derive standardised
estimates of an individual’s intellectual functioning. Where
recent IQ scores from previous assessments were available
(less than 12 months in children; less than 18 months in
adolescents and adults), IQ tests were not repeated.
Clinical measures—co-occurring psychiatric symptoms
The Beck Depression Inventory—Second Edition (BDI-
II; [78]) is a 21-item inventory measuring the severity
of characteristic attitudes and symptoms associated
with depression. Each item contains four possible
responses, which range in severity from 0 (e.g. ‘I do
not feel sad’) to 3 (e.g. ‘I am so sad or unhappy that
I can’t stand it’). Participants are asked to provide
answers based on the way they have been feeling over
the past month, including the assessment day. The
self-report version of the BDI-II was administered to
adult participants. Parents/caregivers completed the
depression subscale of the Beck Youth Inventories
(BYI-II; [79]) for children and adolescents/adults with
mild ID. Adolescents were given the depression
subscale of the BYI-II as self-report.
The Beck Anxiety Inventory (BAI; [80]) is a well-
validated 21-item inventory probing for common symp-
toms of anxiety. Participants rate each item along different
levels of symptom severity experienced over the past
month from 0 = not at all to 3 = severely. The self-report
version of the BAI was administered to adult participants.
Children and adolescents/adults with mild ID were
given the anxiety subscale of the Beck Youth Inven-
tories (BYI-II; [79]) as parent-report, while adoles-
cents completed the anxiety subscale of the BYI-II as
self-report.
The DSM-5 rating scale of attention-deficit/hyperactivity
disorder (ADHD) covers 18 items measuring the presence
of inattention and hyperactive/impulsive symptoms in the
past 6 months, each evaluated on a 0–3 scale (0 = not at
all to 3 = very often). In children, six or more responses
scored with 2 (often) or 3 (very often) to either (or both)
the inattention and hyperactivity/impulsivity domains
indicate clinical concern. Depending on age and abil-
ity level, either parent- or self-report forms were
administered.
Quality control procedures
Appropriate to a multi-centre, cross-national study,
we established quality control procedures around
training, data collection and data entry and checking.
We had cross-site training sessions for collecting clin-
ical data, the ADOS and ADI-R were administered
and scored by qualified/certified personnel and the
study was regularly monitored according to good clinical
practice standards. Of the total number of ADI-R assess-
ments (4–5 ever/diagnostic) administered to participants
(N = 414), N = 162 were re-used from previous studies,
while for the ADOS (N = 364), a total of N = 61 were re-
used (all completed within the previous 12 months). Prior
to data analysis, a series of quality control procedures
were adopted to maximise coherence and comparability
of data. This involved initial randomised double data entry
of 10% of cases at each site for core clinical measures
(e.g. ADI-R, ADOS, IQ data). If a significant level of
incorrect/inconsistent data was identified, all data was
checked against the original paper forms. Other pro-
cedures also included impossible values/range checks
of all items, sub-scales and total scores for interview
and questionnaire measures, duplicated entry detec-
tion and correction, as well as data audits and checks
of scoring algorithms. When missing data was
present, site coordinators were asked to secure the
information if possible.
Across all clinical measures, we have applied a prorat-
ing approach to deal with missing scores. Prorating
replaces the missing score for a given participant with
her/his mean score on other items on the same sub-
scale. Prorating was only applied if less than 20% of
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scores on the same sub-scale were missing. For a higher
percentage of missing scores, prorating was not applied
(i.e. data for these participants was recorded as missing).
Statistical analysis
Statistical analysis was performed with the following
objectives:
(1) To examine whether there are age and/or sex
differences in the severity of ASD symptoms by
comparing individuals with ASD across different
age groups (children, adolescents, adults);
(2) To examine whether differences in age (i.e. ADOS)
or sex (i.e. ADI-R, ADOS) are observed on diagnostic
instruments as well as on continuous measures of
ASD symptomatology (i.e. SRS-2, CSBQ/ASBQ, AQ,
RBS-R, SSP) and whether these patterns are similar or
different across parent- and self-report measures;
(3) To characterise the association between ASD
symptoms and level of intellectual functioning;
(4) To characterise the severity of co-occurring
psychiatric symptoms (i.e. ADHD, anxiety, depression)
in individuals with ASD and to examine how
these relate to age, sex and IQ.
Linear mixed-effects models were fit using a maximum
likelihood estimation method and were executed using
STATA software 14.0 [81]. Differences in ASD symp-
tomatology between individuals with ASD relating to
age, sex and IQ were analysed by restricting the analysis
to participants with ASD only since by definition ASD
participants will score more highly than controls on
ASD symptom measures. Each model (except for ADI-R
diagnostic scores) included fixed main effects for study
schedules (children, adolescents, adults and mild ID)
and sex (male, female), as well as their interaction. In
this paper, we treat age and IQ in two ways. First, both
for clinical ‘face validity’ and to allow the comparison
between the clinical characteristics of the LEAP cohort
to previously published samples—often comprised of
children, adolescents or adults only, with or without
intellectual disability and not with the heterogeneity
present in our cohort by design—we analyse and present
the clinical data in the main paper according to the age/
IQ-defined schedules outlined above. Second, in the
(Additional file 2: Table S1), we present scores on some
of the key measures continuously by age and IQ as this
maximises the power of the large sample and recognises
the arbitrary nature of creating age and IQ ‘groups’ by
‘binning’ the sample into pre-defined age and IQ sub-
groups. For the analysis by schedule, significant main
and interaction effects were further explored using post-
estimation methods including contrasts (Bonferroni-cor-
rected for the number of post hoc comparisons for each
measure separately) and margin plots. Log-transformed
variables were used where appropriate to meet normality
assumptions (RBS-R, SSP). A random effect for site was
included in all models to take into consideration the
multi-level nature of the data, as well as to account for
site heterogeneity across outcome measures. Intraclass
correlation coefficients (ICCs) reflecting the ratio of
between-site variance to total variance are reported
(see Table 4). All models included a continuous measure of
IQ (full-scale IQ) as a covariate (Additional file 3: Table S2).
Linear mixed models report chi-square coefficients and
p value. Effect sizes were calculated following [82] by
dividing the difference in marginal means by the square
root of the variance at the within-participant level. This
measure of effect size is equivalent to Cohen’s d or
standardised difference [83], where an effect size of 0.2 to
0.3 is taken to be a small effect, 0.5 a medium effect
and greater than 0.8 a large effect. For the analyses
reported in the (Additional file 2: Table S1) that treat age
and IQ as continuous variables, we performed linear
mixed-effects models to take into account site effects yet
replacing the categorical age/ability level variable with
continuous measures of chronological age and IQ.
Results
Participant characteristics are shown in Table 3.
Demographics
In the total sample, the mean (SD) chronological age
was 16.9 (5.9) years, with similar distributions of age
for individuals with ASD (M = 16.7, SD = 5.8) and TD/
mild ID individuals (M = 17.2, SD = 5.9), x2(1) = 1.84,
p = .175. Of the 737 participants, 511 were men and
226 were woman (2.3:1 male-female ratio). While
overall, the male-female ratio was significantly but
only slightly higher across individuals with ASD
(2.6:1) relative to TD/mild ID individuals (1:9:1)
(x2(1) = 5.49, p = .019), it was not significant within
each age band (all p > .1). For annual household
income, there was a significant interaction between
diagnosis and schedule (x2(4) = 26.10, p = .0001), with
individual comparisons indicating that household
income was significantly higher in TD children com-
pared to children with ASD (x2(1) = 13.61, p = .0009).
For both paternal (x2(4) = 10.86, p = .028) and mater-
nal education (x2(4) = 19.08, p = .0008), a significant
interaction between diagnosis and schedule was
found. Individual contrasts revealed that the level of
paternal and maternal education was significantly
higher in TD children relative to children with ASD
(x2(1) = 5.11, p = .024 and x2(1) = 6.55, p = .042 respect-
ively). There were no differences in ethnicity between TD/
mild ID and ASD participants overall and within each age
band (all p > .4).
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Site effects
The random effect for site included in all the models
was significant for all the key demographic and diagnos-
tic measures except for sex and ADOS Total and Social
Affect CSS (see Table 4). The ICCs shown in Table 4
indicate that while the effect of site was large for age
(~25%), reflecting the variable recruitment targets across
age schedules and across sites (see Table 1), for other
measures, it was low to moderate, being less than 1% for
sex ratio, less than 6% for IQ, between 9 and 15% for
ADI-R scores and less than 8% for ADOS scores.
Diagnostic ASD measures—sex and age effects
On the ADOS, male ASD participants had significantly
higher CSS Total (x2(1) = 15.81, p = .0001, d = .46) and
CSS Social Affect (SA) (x2(1) = 12.71, p = .0004, d = .44)
than females with ASD and was approaching signifi-
cance for CSS Restricted and Repetitive Behaviours
(RRB) (log-transformed, x2(1) = 3.15, p = .076, d = .22)
(see Table 5 and Fig. 1). A significant interaction
between sex and schedule was found for CSS Total
(x2(4) = 16.97, p= .002) and CSS SA (x2(4) = 13.32, p= .009).
Individual comparisons indicated that only in adolescents,
Table 4 Summary of variation between sites in demographic and behavioural characteristics and level of ASD symptomatology for
individuals with ASD only
Ranges across sites Variance
Minimum Maximum Mean SD Overall mean (SD) Within sites Between sites ICCa x2 sig. value
Chronological age [years:months] 6:07–19:8 24:5–30:6 14:8–25:0 3:2–6:3 16:7 (5:8) 29.87 9.91 .249 p < .0001
Sex, % of male participants 66.1–80.6 72.3 (4.48) 0.46 <.01 <.001b n.s.c
Verbal IQ 45d–70 130–160 93–110 14–21 97 (19) 382.18 12.61 .031 p < .0001
Nonverbal IQ 45d–68 134–150 93–107 16–23 98 (21) 430.82 24.39 .054 p = .0001
Full-scale IQ 40d–73 128–148 96–105 12–22 98 (20) 373.45 16.35 .042 p = .001
ADI-R
Social interaction 0–4 24–29 12–19 6–7 17 (7) 42.26 4.33 .093 p < .0001
Communication 0–3 17–26 9–16 5–5 13 (6) 28.10 4.97 .150 p < .0001
RRB 0–1 8–12 3–5 2–4 4 (3) 6.06 .85 .122 p < .0001
ADOS—CSS
Total 1 10c 5–9 2–3 5 (3) 2.77 .35 <.001b n.s.
SA 1 10c 6–7 2–3 6 (3) 6.88 .11 .016 n.s.
RRB 1 9–10 4–8 2–3 5 (3) 7.29 .60 .076 p < .0001
Sample sizee 22 159 72 54
ICC intraclass correlation coefficient, ADI-R Autism Diagnostic Interview-Revised, ADOS CSS Total, SA, RRB Autism Diagnostic Observation Schedule Calibrated Severity
Scores for Total, Social Affect and Restricted and Repetitive Behaviours, IQ intelligence quotient, n.s. not significant
aThe ratio of between-site variance to total variance
bICC truncated at zero
cThe highest possible score (i.e. ceiling) on the instrument
dThere are 3 individuals with a full-scale IQ <50 (All ASD)
eSample size variation of individuals with ASD across sites (minimum/maximum, mean and standard deviation of number of participants with ASD recruited at sites)
Table 3 Sample characteristics
Total Adults Adolescents Children Mild ID
ASD TD/ID ASD TD ASD TD ASD TD ASD ID
Sex N 437 300 142 109 126 94 101 68 68 29
Males (%) 72.3 65 72.5 67 77 69.1 71.3 61.8 64.7 51.7
Females (%) 27.7 35 27.5 33 23 30.9 28.7 38.2 35.3 48.3
Age
(in years)
M 16.68 17.22 22.79 23.10 14.86 15.33 9.40 9.52 18.09 19.30
SD 5.80 5.94 3.37 3.27 1.73 1.73 1.58 1.54 4.27 4.97
Range 6.08–30.60 6.24 -30.78 18.02–30.60 18.07–30.78 12.07–17.90 12.04–17.99 6.08–11.97 6.24–11.98 11.50–30.19 12.92–30.24
Full-scale
IQ
M 97.61 104.57 103.99 109.15 101.59 106.58 105.29 111.46 65.84 63.39
SD 19.74 18.26 14.82 12.60 15.68 13.18 14.76 12.69 7.70 8.00
Range 40a–148 50–142 76–148 76–142 75–143 77–140 74–148 76–142 40a–74 50–74
ASD autism spectrum disorder, TD typically developing, Mild ID intellectual disability
aThere are 3 individuals with a full-scale IQ <50
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males had significantly higher ADOS CSS Total than
females (x2(1) = 5.93, p= .04, d = .56).
A similar pattern of results was also observed on the
ADI-R, where male ASD participants had more severe
scores than female ASD participants on the Social (x2(1)
= 5.98, p = .015, d = .27), and Restricted and Repetitive
Behaviours (RRB) domain (x2(1) = 7.81, p = .005, d = .30)
but not Communication domain (x2(1) = 2.27, p = .131.
d = .19). No significant effect of schedule was observed
for ADI-R and ADOS scores (see Table 6).
Dimensional ASD measures—sex and age effects
Parent-report and self-report data were analysed separ-
ately. For parent-reported SRS-2 raw scores, no signifi-
cant sex differences were observed within the ASD
group (x2(1) = 0.01, p = .939). There were however
significant differences in SRS-2 raw scores across the
various schedules (x2(3) = 16.82, p = .0008). Follow-up
contrasts (Bonferroni-corrected p values) indicated that
Table 5 Sex differences for key measures for ASD and TD/ID participants (pooled across schedules)
ASD TD/ID
Males Females Males Females
Autism symptomatology measures
ADI—Social 17.01 (6.78) 15.36 (6.89) – –
ADI—Communication 13.55 (5.86) 12.58 (5.33) – –
ADI—RRB 4.57 (2.66) 3.74 (2.52) – –
ADOS—CSS Total 5.73 (2.83) 4.60 (2.49) – –
ADOS—CSS SA 6.31 (2.66) 5.46 (2.56) – –
ADOS—CSS RRB 5.03 (2.86) 4.30 (2.69) – –
SRS-2a 71.50 (11.70) 73.65 (12.18) 47.49 (9.97) 48.07 (9.17)
SRS-2b 62.37 (9.91) 66.48 (11.14) 48.48 (6.08) 46.55 (6.13)
CSBQa 46.86 (17.01) 46.94 (15.62) 7.55 (12.56) 6.30 (8.50)
ASBQa 32.78 (16.76) 32.61 (16.55) 14.67 (15.17) 22.11 (20.76)
ASBQb 30.34 (15.08) 37.37 (15.75) 8.11 (8.49) 7.53 (8.97)
AQ—child 94.26 (18.00) 92.76 (17.39) 45.21 (17.95) 29.70 (10.07)
AQ—adolescents 95.78 (17.66) 96.32 (18.02) 48.92 (20.43) 44.75 (20.67)
AQ—adults 81.03 (18.86) 88.06 (20.78) 49.46 (14.88) 43.10 (14.05)
RBS-Ra 17.16 (14.01) 15.76 (13.48) 2.58 (9.43) 2.42 (5.02)
SSPa 138.12 (27.78) 138.15 (26.83) 175.17 (17.00) 175.75 (17.46)
Psychiatric symptom measures
ADHD—inattentivenessa 4.75 (3.13) 4.05 (3.18) 1.34 (2.19) 1.23 (2.58)
ADHD—hyperactivity/impulsivitya 2.98 (2.91) 2.47 (2.71) 0.57 (1.57) 0.54 (1.63)
Anxietya 48.52 (8.68) 49.14 (9.91) 40.27 (7.75) 38.64 (6.00)
Depressiona 51.42 (11.82) 50.44 (8.09) 41.76 (10.47) 39.77 (4.97)
ADI Autism Diagnostic Interview–Revised, ADOS CSS Total, SA, RRB Autism Diagnostic Observation Schedule Calibrated Severity Scores for Total, Social Affect and
restricted and repetitive behaviours; SRS-2 Social Responsiveness Scale–2, CSBQ, ASBQ Children’s Social Behaviour Questionnaire (parent-report, administered to
children, adolescents), Adults’ Social Behaviour Questionnaire (parent-report, administered to adults) scores cannot be pooled across age groups, RBS-R Repetitive
Behavior Scale–Revised, SSP Short Sensory Profile, AQ Autism Spectrum Quotient (children, adolescents and adult version; scores cannot be pooled across
age group
aParent-report
bSelf-report
Fig. 1 Boxplot of ADOS CSS Total scores by sex and for each schedule
(ASD participants only)
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adults had significantly lower SRS-2 raw scores com-
pared to children (x2(1) = 13.93, p = .0006, d = .62) and
adolescents (x2(1) = 10.34, p = .0039, d = .52) (see Fig. 2)
but not compared to adolescents/adults with ASD and
mild ID (x2(1) = 4.82, p = .084, d = .49). For parent-
reported SRS-2 T scores (age- and sex-adjusted), while
there were no significant sex differences within the ASD
group (x2(1) = 2.58, p = .108), SRS-2 T scores differed
significantly across the various schedules (x2(3) = 65.70,
p < .0001). Follow-up contrasts indicated that adults
had significantly lower SRS-2 T scores compared to
children (x2(1) = 51.16, p < .0001, d = 1.19) and adoles-
cents (x2(1) = 46.52, p < .0001, d = 1.10), as well as
compared to adolescents/adults with ASD and mild
ID (x2(1) = 12.43, p = .001, d = .80) (see Fig. 3). The
interaction between sex and schedule was not signifi-
cant (x2(3) = 6.43, p = .169).
Adolescents and adults also completed the SRS-2 as
self-report. On this measure, females had significantly
higher SRS-2 raw scores (x2(1) = 6.81, p = .009, d = .49)
and T scores (x2(1) = 7.02, p = .008, d = .50) than males
overall. A significant interaction between schedule and
sex was also observed for SRS-2 raw scores (x2(1) = 9.60,
p = .008) and SRS-2 T scores (x2(1) = 9.89, p = .007).
Follow-up tests revealed that adult ASD females
reported significantly higher SRS-2 raw scores (x2(1) =
8.38, p = .008, d = .60) and T scores (x2(1) = 8.63, p = .007,
d = .60) than adult ASD males, but there were no sex
differences in adolescents.
In contrast to parent-reported SRS-2 T scores, adults
had significantly higher self-reported SRS-2 T scores
(x2(1) = 6.57, p = .010, d = .36) and SRS-2 raw scores
(x2(1) = 6.55, p = .011, d = .36) than adolescents. On both
the parent-report versions of the CSBQ and ASBQ,
which were analysed separately due to differences in
item and sub-scale structure, no main effect of sex or
schedule and no significant sex by schedule interaction
were observed. In contrast, for adults with ASD
Table 6 ADI-R and ADOS scores by schedule for individuals with ASD only
Total Adults Adolescents Children Mild ID
ADI-R—Social 16.54 (6.85)
n = 411
15.31 (6.87)
n = 132
17.27 (6.55)
n = 123
15.38 (6.76)
n = 94
19.45 (6.57)
n = 62
ADI-R—Communication 13.13 (5.72)
n = 414
12.19 (5.76)
n = 132
13.63 (5.63)
n = 123
13.29 (5.75)
n = 96
13.87 (5.62)
n = 63
ADI-R—RRB 4.33 (2.65)
n = 414
4.23 (2.62)
n = 132
4.28 (2.71)
n = 123
4.68 (2.79)
n = 96
4.14 (2.36)
n = 63
ADOS—CSS Total 5.39 (2.78)
n = 362
4.84 (2.80)
n = 110
5.78 (2.77)
n = 102
4.98 (2.65)
n = 91
6.39 (2.65)
n = 59
ADOS—CSS SA 6.06 (2.65)
n = 362
5.49 (2.70)
n = 110
6.44 (2.55)
n = 102
5.55 (2.58)
n = 91
7.25 (2.38)
n = 59
ADOS—CSS RRB 4.81 (2.83)
n = 362
4.80 (2.76)
n = 110
4.84 (2.61)
n = 102
4.84 (3.07)
n = 91
4.75 (3.00)
n = 59
ASD (autism spectrum disorder), Mild ID (intellectual disability), ADI-R Autism Diagnostic Interview–Revised, ADOS Autism Diagnostic Observation Schedule
Fig. 2 SRS-2 raw scores (parent-report) by chronological age
(ASD participants only)
Fig. 3 SRS-2 Total scores (parent-report) by chronological age
(ASD participants only)
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completing the ASBQ as self-report, females reported
significantly higher scores than males (x2(1) = 7.57,
p = .006, d = .48).
Data on the AQ was analysed separately for children,
adolescents and adults because different versions of the
measure were used. On the Adult-AQ (self-report), sex
differences were approaching significance with females
having higher scores than males (x2(1) = 3.40, p = .065,
d = .39). Some group effects were found on the AQ-
Adolescent, where adolescents with ASD and ID had
significantly higher AQ scores than adolescents with
ASD without ID (x2(1) = 7.69, p = .006, d = .93).
Prior to analysis, total scores of the RBS-R were log
transformed to meet normality assumptions. There
was no significant effect of sex (x2(1) = .32, p = .569)
but a significant main effect of schedule (x2(3) =
27.13, p < .0001), with adults having significantly lower
RBS-R scores relative to children (x2(1) = 26.20, p < .0001,
d = .91) and adolescents (x2(1) = 11.98, p = .001, d = .57).
There was no significant interaction effect between sex
and schedule.
On the SSP (using log-transformed total scores), no
main effect of sex or schedule and no significant sex by
schedule interaction were observed.
Intellectual functioning
The mixed-effects analysis revealed a significant inter-
action between schedule and diagnosis for full-scale IQ
scores (x2(4) = 25.13, p = .0001, see Table 3), with signifi-
cantly higher IQ scores in TD individuals compared to
participants with ASD in the adult (x2(1) = 8.60, p = .01,
d = .39), adolescent (x2(1) = 7.79, p = .02, d = .38) and
children age groups (x2(1) = 8.23, p = .017, d = .37). No
significant differences in intellectual functioning were
found between individuals with/without ASD and
mild ID.
Examining the association between measures of ASD
symptomatology and IQ (full-scale IQ) in individuals
with ASD only, there were significant, albeit weak
negative correlations between ADOS Total CSS and IQ
(r = −.23; n = 358; p < .0001), as well as between ADOS
Social Affect CSS and IQ (r = −.23; n = 358; p < .0001),
with higher IQs being associated with lower symptom
levels. There was no significant association between
ADOS RRB CSS and IQ. Scores on the ADI-R Social
domain (r = −.22; n = 404; p < .0001) and ADI-R Commu-
nication domain (r = −.12; n = 407; p = .04), but not ADI-R
RRB domain (r = .01; n = 407; p = .782), were also signifi-
cantly associated with IQ. On dimensional measures of
ASD symptom severity significant negative correla-
tions between SRS-2 Total T scores (parent-report)
and IQ (r = −.23; n = 350; p < .0001) see (Additional
file 3: Table S2), between SRS-2 raw scores (parent-
report) and IQ (r = −.26; n = 350; p < .0001), between
ASBQ Total scores (parent-report) and IQ (r = −.38; n
= 94; p = .0002) and between RBS-R Total scores and IQ
(r = −190; n = 340; p = .0003) were observed. Scores on the
SRS-2 (T scores and raw scores for self-report), AQ (child,
adolescent and adult version), SSP and CSBQ (parent-re-
port)/ASBQ (self-report) were not significantly associated
with level of intellectual functioning.
Psychiatric symptom measures (analysed within the ASD
participants only)
Due to limited availability of self-report data (TD: n = 14;
ASD: n = 18), only parent-reported levels of ADHD symp-
toms were analysed. A large proportion of children with
ASD (here defined as chronological age <17 years accord-
ing to the ADHD symptom checklist) scored in the clin-
ical range on the inattentiveness (51%) and hyperactivity/
impulsivity ADHD domains (28%). In contrast, the num-
ber of adolescents and adults with ASD that met clinical
cut-off on these measures was somewhat lower (inatten-
tiveness 41%; hyperactivity/impulsivity 13%). Among
participants with ASD, males scored significantly higher
than females on the inattentiveness domain (x2(1) = 4.73,
p = .030, d = .22) and hyperactivity/impulsivity domain
(x2(1) = 3.99, p = .046, d = .22). There was also a significant
effect of schedule on both the inattentiveness domain
(x2(3) = 26.30, p < .0001) and hyperactivity/impulsivity
domain (x2(3) = 71.73, p < .0001), with adults with
ASD having significantly lower symptom levels across
these domains compared to children (inattentiveness:
x2(1) = 20.72, p < .0001, d = .78; hyperactivity/impulsiv-
ity: x2(1) = 69.35, p < .0001, d = 1.32) and adolescents
(inattentiveness: x2(1) = 14.94, p = .0003, d = .54; hyper-
activity/impulsivity: x2(1) = 11.80, p = .002, d = .50).
However, while no differences were observed between
children and adolescents in inattentive symptom
levels (x2(1) = 0.60, p = .438), children with ASD had
significantly higher levels of hyperactivity/impulsivity
symptoms compared to adolescents with ASD (x2(1)
= 24.98, p < .0001, d = .87). There was no significant
interaction effect between sex and schedule.
Among participants with ASD completing the BAI or
BYI-II as self-report, 24% of adults (26 of 108; i.e. raw
anxiety scores 21+) and 18% of adolescents (12 of 66;
sex-and age-adjusted T score 60+) scored in the moder-
ate/severe clinical range. In children (TD: n = 51; ASD:
n = 83) and adolescents/adults with mild ID (mild ID: n =
10; ASD: n = 29), symptoms of anxiety were assessed by
the BYI-II through parent-report. In addition, some ado-
lescents without ID (TD: n = 4; ASD: n = 17) received the
BYI-II as parent-report. The proportion of individuals
with ASD considered to present with a moderate/severe
severity level in anxiety symptoms (same clinical cut-offs
apply as above) was 12% for children (10 of 83), 7% for
adolescents (2 of 29) and 27% for adolescents/adults with
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mild ID (4 of 15). No significant effects of sex or schedule
were found across all anxiety scales.
For depressive symptoms as measured by the BDI-II
or BYI-II as self-report, it was found that among par-
ticipants with ASD, 22% of adults (24 of 107; raw de-
pression scores of 21+) and 27% of adolescents (18 of
67; i.e. T score 60+) scored in the moderate to severe
clinical range. In adults with ASD, females reported
significantly higher depressive symptoms than males
(x2(1) = 11.66, p = .0006, d = .72) but not in adoles-
cents (x2(1) = .44, p = .507). The depression subscale of
the BYI-II was administered to children (TD: n = 53;
ASD: n = 86), adolescents/adults with mild ID (mild
ID: n = 10; ASD: n = 29) and adolescents without ID
(TD: n = 4; ASD: n = 17) and completed by their par-
ents. Sixteen percent of children (14 of 86), 29% of
adolescents (5 of 17) and 28% of adolescents/adults
with mild ID (8 of 29) had scores in the moderate/severe
clinical range (i.e. sex- and age-adjusted T score of 60+).
Association between psychiatric symptoms and
intellectual functioning
Among participants with ASD, the association between
psychiatric symptoms (depression, anxiety, inattention
and hyperactivity/impulsivity) and intellectual function-
ing (full-scale IQ) was also assessed. There were
significant but weak negative correlations between parent-
reported symptoms of inattention and IQ (r = −.20; n =
345; p < .0001), as well as between hyperactivity/impul-
sivity and IQ (r = −.17; n = 345; p = .001). On measures
of anxiety, no significant correlation was found be-
tween self-report measures and IQ in adolescents (r =
−.10; n = 66; p = .421), as well as between parent-report
measures and IQ in children, adolescents and adoles-
cents/adults with mild ID (r = −.05; n = 125; p = .555).
There was however a significant, albeit weak negative
correlation between anxiety symptoms (self-report) and
IQ in adults with ASD (r = −.23; n = 108; p = .017). No
significant association between depressive symptoms
(parent- or self-report) and IQ was observed across all
schedules (all p > 0.1).
Associations between ASD measures
Figure 4 shows the associations between the different
questionnaire ASD symptom measures separately for the
ASD and TD/ID participants. Within the ASD group, as
expected, the parent-report global ASD symptom
measures (SRS, CSBQ,/ASBQ, AQ) were highly inter-
correlated (all r values >.60, p < .0001). The RBS-R meas-
uring repetitive behaviour symptoms (r from .56 to .73,
all p < .0001) and the SSP measuring sensory symptoms
(higher scores on the SSP indicate lower symptomatol-
ogy; r from −.44 to −.70, all p < .0001) were also strongly
inter-correlated with the global symptom measures.
Parent-report of ASD symptoms (SRS, CSBQ/ASBQ)
was moderately to strongly associated with parent-report
of both ADHD inattention and hyperactivity/impulsivity
symptoms (all r > .38, p < .0001) but the parent-report
AQ less so (see Fig. 4).
Fig. 4 Heatmap of correlations between ASD and psychiatric symptom measures (ASD left diagonal; TD/ID participants right diagonal)
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Discussion
Clinical characteristics of the EU-AIMS LEAP cohort
The EU-AIMS LEAP cohort is a large, well-characterised
sample of individuals with ASD and controls ranging from
young children to adults with a fairly wide range of IQ.
The main groups of adult, adolescent and child partici-
pants with ASD and controls have IQs in the typical range
with means close to the population average. The group of
purposively sampled participants with and without ASD
with mild ID (IQ range 50 to 74) is relatively small (n = 68
ASD; n = 29 non-ASD). Although the LEAP sample has
an elevated IQ compared to the total population of indi-
viduals with ASD, of whom around 50% have an intellec-
tual disability [8, 9], it is rare for experimental studies of
biomarkers to include any participants with an IQ below
75. Participants were purposively sampled to enable in
depth experimental characterisation of potential bio-
markers (including MRI scans), and therefore we set a
lower IQ limit of 50; however, we enrolled 3 participants
with lower IQ but who were capable of completing all our
minimal assessments. It is a notable limitation of the rep-
resentativeness of the current sample that in common
with many studies, we excluded ASD participants with
severe intellectual disability and this remains a challenge
to scientific enquiry, in particular perhaps in the domain
of cognitive neuroscience [84]. Related to this point, we
note that the ADOS CSS scores were somewhat lower
overall in the current LEAP sample (Table 7) compared to
other large cohorts such as the Simons Simplex Collection
[85] which predominantly consists of clinically ascertained
samples and included participants with lower IQ than in
the present volunteer research sample where IQ was
restricted to IQ ≥50 due to the experimental protocol.
Reflecting recruitment from multiple research sites in
four countries from existing research cohorts and from
different clinic and volunteer sources, there were signifi-
cant site effects on the core characterisation measures
identified in the mixed-effects models. However, ICCs
were mostly below 10% (the exception was age which
reflects that some sites only sampled across some of the
schedule groups). This reflects that there was consider-
able heterogeneity of cognitive ability levels and scores
on core diagnostic measures within each site but system-
atic differences between sites on these measures ranged
from minimal to moderate only. The quality control
procedures we implemented give us confidence in the
coherence and comparability of data collected across
six sites.
In addition to the well-established diagnostic measures
ADI-R and ADOS, we have further characterised ASD
symptomatology using a range of dimensional parent-
report (and, in adolescents and adults, self-report)
measures of global ASD symptom severity (SRS-2,
CSBQ/ASBQ, AQ) as well as specific measures of
repetitive (RBS-R) and sensory (SSP) symptoms. Further-
more, we have also acquired questionnaire measures of
the most commonly occurring psychiatric symptoms
found in individuals with ASD [7, 40]—ADHD, anxiety
and depression. In terms of the biomarker discovery
aims of the EU-AIMS LEAP project overall [46–49], this
comprehensive clinical characterisation of such a large
sample will enable us to test for associations between
putative biomarkers while including potential moderat-
ing or stratification factors including sex, age, IQ and
co-occurring psychiatric symptoms.
Sex differences in ASD symptoms
We examined sex differences in ASD severity that have
been reported in some but not all previous studies [18].
Across the whole sample, males with ASD had more
severe symptom scores than females on some domains
of the ADOS and the ADI-R, including both social com-
munication and repetitive behaviours. Some previous
studies have found higher levels of repetitive behaviours
but not higher social communication symptoms in
males vs. females [19, 21], but others have reported
higher levels of social communication symptoms in
females [22, 23]. In contrast, we found no sex differences
on the parent-report questionnaire measures of ASD
symptoms (SRS-2, CSBQ/ASBQ, RBS-R and SSP). Diag-
nostic measures like the ADOS and ADI-R differ from the
parent-report ASD symptom questionnaires in several
ways, including that the ADOS is an observer-rated
measure of current ASD symptoms and the ADI-R
algorithm domain scores assess historical symptom
severity (4 to-5 years and ever). The parent-report and
self-report questionnaires by design are intended to meas-
ure symptoms or traits in a more continuous or dimen-
sional fashion compared to these diagnostic tools.
However, it remains unclear as to why males had higher
ASD symptom severity scores on the diagnostic measures
but not the questionnaire measures. One possible explan-
ation is a bias or expectation of researchers administering
the ADOS and ADI-R, perhaps due to expectations about
sex differences—for example awareness of female com-
pensatory behaviours and strengths—in ASD symptom
profiles. Another possibility is that parent-reported ques-
tionnaire measures are influenced by parents’ gender
stereotypes. Alternatively, diagnostic measures that tap
variation in clinical level symptoms and ‘trait’ measures of
individual differences across populations of the ASD
phenotype are of a different kind, although recent twin
studies suggest that they share a common genetic archi-
tecture [86]. A final point to note is that, with the notable
exception of the SRS-2, none of the other measures have
sex-specific norms which should be a future goal for
further psychometric development of ASD symptom
measures (Table 8) [18, 87].
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Age and IQ differences in ASD symptoms
On the diagnostic measures (ADOS and ADI-R), there
were no age differences in symptom severity. However,
on the SRS-2 (a parent-report global measure of ASD
symptoms), adults with ASD had lower symptom sever-
ity than adolescents and children and the ASD group
with mild ID. A similar pattern was found on the
parent-report measure of restricted, repetitive and ste-
reotyped behaviour, the RBS-R, with adults with ASD
scoring lower than all other groups. The findings were
corroborated when age was analysed in a continuous
fashion rather than according to the age and ability
schedule presented here (see Additional file 2: Table S1).
This is consistent with a number of other studies show-
ing reduced ASD symptoms in adulthood, including
samples followed longitudinally since childhood [34–36].
With only one time-point of data, we cannot yet deter-
mine if the age differences in symptom severity are due to
cross-sectional differences in sampling or true in nature
but the accelerated longitudinal design of the LEAP study
will allow us to investigate this in the future.
Social communication symptoms as measured by the
ADOS Social Affect CSS and ADI-R Social and Commu-
nication domain scores were moderately negatively asso-
ciated with IQ—with higher scores in those with lower
IQ—but this was not the case for the ADOS RRB CSS
or the ADI-R RRB domain. On the continuous measures
of ASD symptomatology, the SRS-2 and RBS-R were
also correlated negatively with IQ but the AQ and SSP
were not. Note, however, that even when these associa-
tions were significant in this large and well-powered
sample, the variance in common between IQ and symp-
tom measures (r-squared) was only ~5%. This is in line
with previous studies where low IQ has been modestly
but significantly associated with higher levels of ASD
symptom severity [41, 42]. This may, in part, reflect the
fact that many diagnostic and dimensional measures of
ASD symptomatology include a mixture of developmen-
tal abilities or skills and frank atypical behaviours, in
particular for children and adolescents. Alternatively,
individuals with ASD with higher cognitive ability
might develop compensatory or alternative strategies
to develop social communication skills resulting in
slightly reduced symptom presentation. When looking
at associations between putative ASD biomarkers and
measures of the core ASD phenotype and co-occurring
psychiatric symptoms, it will be important to consider the
effect of IQ as associations dependent or independent of
intellectual ability might indicate different neurobiological
mechanisms.
Co-occurring psychiatric symptoms
Among individuals with ASD, males had higher levels of
inattentive and hyperactive/impulsive symptoms than
females and both inattentive and hyperactive/impulsive
symptoms were lower in adults than in adolescents, as
has been found in non-ASD samples [88]. Female adults
with ASD reported higher levels of depressive, but not
anxiety, symptoms than males. This finding is potentially
important to emphasise so that clinicians do not over-
look possible symptoms of depression in adult females
with ASD. The proportion of individuals with elevated
anxiety scores is lower in the current sample than in
many previous studies, but note that we were using
questionnaire screening measures of psychiatric symp-
toms and not diagnostic instruments where 30 to 40% of
individuals with ASD have met criteria for an anxiety
disorder [7, 89]. Parent-report and self-report of co-
occurring psychiatric symptoms were weakly negatively
correlated with IQ, consistent with some previous stud-
ies [38, 45]. Most parent-report measures of ASD symp-
toms were moderately to strongly associated with
parent-report of both ADHD inattention and hyperactiv-
ity/impulsivity symptoms [90] (and similarly for self-
reported ASD symptoms and self-reported associated
psychiatric symptoms) but the AQ somewhat less so
(see Fig. 4). Parent-report of ASD symptoms was only
moderately associated with self-reported anxiety and
depression, as has been previously reported in ASD [91]
and non-ASD samples [92]. We note that the validity of
assessments of psychiatric symptoms in samples of individ-
uals with ASD is unknown, perhaps especially with respect
to anxiety symptoms, although the measures we chose are
widely used, including in previous studies in ASD.
Self-report measures of the ASD phenotype
In contrast to the higher symptom scores in males com-
pared to females on the diagnostic measures the ADOS
and ADI-R (but not on parent-report questionnaire
measures of symptom severity), in a sub-sample of
adults and adolescents with ASD able to self-report on
the SRS-2, ASBQ and AQ female adults reported higher
levels of symptoms than males. A similar pattern has
been reported in previous studies [93, 94] and may be
due to higher self-reflective ability in adult females than
males with ASD, identity-driven ‘biases’ or truly height-
ened ASD traits. The different pattern of findings for
self- vs. parent-report of ASD symptoms might also indi-
cate an effect described as ‘masking’ or ‘camouflage’ in
(adult and adolescent) females with ASD whereby symp-
toms appear ameliorated to observers (in this case par-
ents) due to compensatory social engagement skills [18].
We also found contrasting patterns of self- vs. parent-
report of ASD symptoms with respect to age, with
parent report SRS-2 scores showing lower symptoms in
adults than adolescents but self-report finding the
reverse. One important contribution the current study
makes is the inclusion of a range of ascertainment
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methods of ASD symptoms including clinician observa-
tion and both parent- and self-report. These are import-
ant considerations both for identifying biomarkers
associated with the ASD phenotype and potentially for
use as outcome measures in future clinical trials. The
issues raised are complex and go beyond the sample
description contained in the current paper but in-
clude what it might mean if biomarkers relate to one
type of measure but not another and what measures
(e.g. clinician-report vs. parent-report vs. self-report)
should be used as outcome measures in clinical trials
and who gets to make these choices [61].
Relevance of in-depth clinical characterisation for biomarker
analysis
Within the framework of the NIH Research Domain
Criteria (RDoC; [95]) initiative, core neurobiological
or genetic systems vulnerabilities might map better
onto neurodevelopmental or neurocognitive systems
than the disorder-specific behavioural domains. This
guided the ‘deep phenotyping’ approach we have
taken in the EU-AIMS LEAP study to characterise the
cohort not only comprehensively in terms of their ASD
and co-occurring disorders behavioural phenotype but
also at the level of structural and functional brain
development, neurocognitive function and biochemical
and genomic assays [46], consistent with other ‘big
data’ approaches in psychiatry [17].
Choices as to which ASD symptom measures should
be used for biomarker validation need to be informed by
a number of considerations. These include statistically
guided principles regarding distributions (in both cases
and controls). Across the range of ASD phenotypic mea-
sures acquired in the LEAP sample, some are highly
skewed even in the ASD sample (e.g. SSP), while other
measures are dimensional and more akin to ‘trait’ mea-
sures and have considerable variation in both the ASD
and control samples (e.g. SRS-2, CSBQ/ASBQ, AQ).
Although skewed data can be statistically transformed
back towards normality, non-parametric, ordinal or
categorical approaches can also be adopted but this
needs to be mapped back onto the clinical phenomena
that any phenotypic measure is assaying. Another con-
sideration will be the extent to which potential bio-
markers are examined in terms of their association with
‘domains’ or ‘sub-domains’ of the ASD phenotype, for
example within the repetitive behaviours domain there is
some evidence at the genetic level that different genes
might associated with ‘lower’ vs. ‘higher’ levels of repeti-
tive behaviour [96]. Finally, we have reported both raw
and age and sex-normed T scores on an instrument such
as the SRS-2 in this clinical paper but for biomarker
analysis raw un-adjusted scores allows a more neutral
mapping onto the phenotypic behaviour.
The diagnostic measures have particular characteristics
that might make them useful at different levels/stages in
the biomarker validation process. For example, the ADI-R
diagnostic algorithm domain scores are based on past his-
tory and in particular the early developmental period (age 4
to 5 years) when it has been proposed that ASD presenta-
tion is most prototypical [97]. On the other hand, the
ADOS is a researcher/clinician-rated observational measure
and is therefore less likely to suffer from the same potential
‘halo effect’ when a parent is rating (for example, on two
questionnaires) different behavioural characteristics (e.g.
ASD and ADHD), thus reducing systematic rater bias.
We have also found modest but robust associations
between severity of ASD symptoms and participant
characteristics such as age, sex and IQ as well as with
levels of co-occurring psychiatric symptoms. These con-
siderations will be important for considering the sensi-
tivity and specificity of any associations found between
the ASD phenotype and potential biomarkers. The asso-
ciations between potential stratification biomarkers and
ASD symptoms can be tested in models that include
these factors where they are associated with the ASD
phenotypic scores themselves. The LEAP cohort has
purposively been ‘deep phenotyped’ at a number of levels
so that biomarker detection analysis in this large sample
can take account of these factors.
Conclusions
The in-depth clinical characterisation of the EU-AIMS
LEAP cohort will allow us to test how a wide range of
potential biological and neurocognitive biomarkers [46–49]
are associated with both diagnostic and more dimensional
measures of the core ASD phenotype. We will be able to
test whether these associations are influenced by the pres-
ence of commonly co-occurring psychiatric symptoms, as
well as whether they differ across males and females or ac-
cording to age or intellectual ability. In addition, the pattern
of associations we have found in the LEAP cohort differs
across the clinician observational and parent- vs. self-report
questionnaire measures and both conceptual and methodo-
logical considerations should guide how these issues are
addressed in stratification biomarker analysis. The inclusion
of multiple dimensional measures of ASD symptom
severity will allow us to test which measure relates best to
neurobiological or neurocognitive biomarkers and is most
sensitive to change over time. This would have important
implications for choosing appropriate outcome measures in
future clinical trials. We anticipate that as the EU-AIMS
LEAP cohort is followed into the future, it will become a
key resource of autism discovery science.
Endnotes
1At four additional sites (UCAM, CIMH, UCBM and
UMCU) following assessment, a minority of participants
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with ASD were allocated to the Mild ID group due to
measured IQ falling in the 50–74 range (see Table 1).
2There are three individuals with a Full-scale IQ <50
in the sample (all ASD).
Additional files
Additional file 1: Table S3. (DOCX 22 kb)
Additional file 2: Table S1. Predicted effect of age and IQ on ADOS
Calibrated Severity Scores. (DOCX kb)
Additional file 3: Table S2. Predicted effect of age and IQ on parent-
and self-report ASD measures. (DOCX kb)
Abbreviations
ADHD: Attention-deficit/hyperactivity disorder; ADI-R: Autism Diagnostic
Interview-Revised; ADOS: Autism Diagnostic Observation Schedule;
AQ: Autism Spectrum Quotient; ASBQ: Adult Social Behaviour
Questionnaire; ASD: Autism Spectrum Disorder; BAI: Beck Anxiety Inventory;
BDI-II: Beck Depression Inventory—Second Edition; BYI-II: Beck Youth
Inventories; CIMH: Central Institute of Mental Health; CSBQ: Children’s
Social Behaviour Questionnaire; CSS: Calibrated Severity Scores;
DSM-5: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition;
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition;
DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
text-revision; EU-AIMS: European Autism Interventions—A Multicentre Study for
Developing New Medications; ICC: Intraclass correlation coefficient;
ICD-10: International Statistical Classification of Diseases and Related Health
Problems, 10th Revision; ID: Intellectual disability; IoPPN: Institute of Psychiatry,
Psychology and Neuroscience; IQ: Intelligent quotient; KCL: King’s College
London; LEAP: Longitudinal European Autism Project; MRI: Magnetic resonance
imaging; P: Parent-report; RBS-R: Repetitive Behavior Scale-Revised;
RDoC: Research Domain Criteria; RRB: Repetitive and Restricted Behaviours;
RUNMC: Radboud University Nijmegen Medical Centre; S: Self-report; SA: Social
Affect; SRS-2: Social Responsiveness Scale, Second Edition; SSP: Short Sensory
Profile; TD: Typically developing; UCAM: Autism Research Centre, University of
Cambridge; UCBM: University Campus Bio-Medico; UMCU: University Medical
Centre Utrecht; WAIS-III/IV: Wechsler Adult Intelligence Scale—Third Edition/
Fourth Edition; WASI-II: Wechsler Abbreviated Scales of Intelligence—Second
Edition; WISC-III/IV: Wechsler Intelligence Scale for Children—Third Edition/
Fourth Edition
Acknowledgements
We thank all participants and their families for their efforts to participate in
the study.
Funding
This work was supported by EU-AIMS (European Autism Interventions),
which receives support from the Innovative Medicines Initiative Joint
Undertaking under grant agreement no. 115300, the resources of which
are composed of financial contributions from the European Union’s Sev-
enth Framework Programme (grant FP7/2007-2013), from the European
Federation of Pharmaceutical Industries and Associations companies’ in-
kind contributions, and from Autism Speaks.
Availability of data and materials
The datasets generated and/or analysed during the current study are not
publicly available due to an embargo period but are available from the
corresponding author on reasonable request.
Authors’ contributions
TC, EL, JT, DG, BA, ToB, SBC, CB, SB, TB, MB, DB, BC, FDA, GD, SD, CE, VF, PG,
LH, JH, RJH, MHJ, EJHJ, PK, MCL, XLD, MVL, DJL, RM, LM, AML, CM, LOD, MO,
BO, GP, AMP, RS, ES, RT, HT, JW, SCRW, MPZ, WS, DGM and JKB designed the
study and developed acquisition and/or analysis protocols. CW, DC, JA, SA,
SB, CB, CB, YdB, IC, JF, HH, JI, NM, BR, ANVR, JS and ASJC collected the data.
TC wrote the first and final draft of the manuscript. TC, EL, JT, EJHJ, JB, ToB,
SBC, SB, SB, TB, DG, LMH, MHJ, MCL, BO, GP, AMP, ASJC, ES, HT, WS, DGM
and JKB contributed to writing the manuscript. All authors read and approved
the final manuscript.
Competing interests
Jan Buitelaar has been in the past 3 years a consultant to/member of
advisory board of/and/or speaker for Janssen Cilag BV, Eli Lilly, Lundbeck,
Shire, Roche, Novartis, Medice and Servier. He is not an employee of any of
these companies and not a stock shareholder of any of these companies. He
has no other financial or material support, including expert testimony, patents,
and royalties. Sven Bölte receives royalties for the German and Swedish
KONTAKT manuals and adaptations of the ADI-R, ADOS, and SRS from Hogrefe
Publishers. Bölte has in the last 3 years acted as an author, consultant or lecturer
for Shire, Medice, Roche, Eli Lilly, Prima Psychiatry, GLGroup, System Analytic,
Kompetento, Expo Medica, Prophase and receives royalties for text books and
diagnostic tolls from Huber/Hogrefe, Kohlhammer and UTB. Lindsay Ham,
Xavier Liogier D’Ardhuy, Joerg Hipp, Pilar Garcés and Will Spooren are employees
at F. Hoffmann-La Roche Ltd. Gahan Pandina is an employee at Janssen. Andreas
Meyer-Lindenburg has received consultant fees and travel expenses from Alexza
Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Defined Health, Decision
Resources, Desitin Arzneimittel, Elsevier, F. Hoffmann-La Roche, Gerson Lehrman
Group, Grupo Ferrer, Les Laboratoires Servier, Lilly Deutschland, Lundbeck
Foundation, Outcome Sciences, Outcome Europe, PriceSpective, and Roche
Pharma and has received speaker’s fees from Abbott, AstraZeneca, BASF,
Bristol-Myers Squibb, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Pfizer Pharma,
and Servier Deutschland. Tobias Banaschewski has served in an advisory or
consultancy role for Actelion, Hexal Pharma, Lilly, Medice, Novartis, Oxford
outcomes, Otsuka, PCM scientific, Shire and Viforpharma. He received conference
support or speaker’s fee by Medice, Novartis and Shire. He is/has been involved
in clinical trials conducted by Shire and Viforpharma. He received royalties from
Hogrefe, Kohlhammer, CIP Medien, and Oxford University Press. The present work
is unrelated to the above grants and relationships. The other authors declare that
they have no competing interests.
Consent for publication
Consent for publication was obtained from all participants prior to the study.
Ethics approval and consent to participate
All participants (where appropriate) and their parent/legal guardian provided
written informed consent. Ethical approval for this study was obtained
through ethics committees at each site (Table a):
Site Ethics committee ID/reference no.
KCL London Queen Square Health Research
Authority Research Ethics Committee
13/LO/1156
UCAM
RUNMC Radboud Universitair Medisch Centrum
Instituut Waarborging Kwaliteit en Veiligheid
Commissie Mensgebonden Onderzoek
Regio Arnhem-Nijmegen (Radboud
University Medical Centre Institute Ensuring
Quality and Safety
Committee on Research Involving Human
Subjects
Arnhem-Nijmegen)
2013/455
UMCU
CIMH UMM Universitatsmedizin Mannheim,
Medizinishe Ethik Commission II
(UMM University Medical Mannheim,
Medical Ethics Commission II)
2014-540N-MA
UCBM Universita Campus Bio-Medica De Roma
Comitato Etico (University Campus
Bio-Medical Ethics Committee De Roma)
18/14 PAR
ComET CBM
KI Centrala Etikprovningsnamnden (Central
Ethical Review Board)
32-2010
Charman et al. Molecular Autism  (2017) 8:27 Page 18 of 21
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Psychology, Institute of Psychiatry, Psychology and
Neuroscience, King’s College London, De Crespigny Park, Denmark Hill,
London SE5 8AF, UK. 2Sackler Institute for Translational Neurodevelopment,
Institute of Psychiatry, Psychology and Neuroscience, King’s College London,
De Crespigny Park, Denmark Hill, London SE5 8AF, UK. 3Department of
Forensic and Neurodevelopmental Sciences, Institute of Psychiatry,
Psychology and Neuroscience, King’s College London, De Crespigny Park,
Denmark Hill, London SE5 8AF, UK. 4Department of Neuroimaging, Institute
of Psychiatry, Psychology and Neuroscience, King’s College London, De
Crespigny Park, Denmark Hill, London SE5 8AF, UK. 5Neurospin Centre CEA,
Saclay 91191, Gif sur Yvette, France. 6Autism Research Centre, Department of
Psychiatry, University of Cambridge, Douglas House, 18b Trumpington Road,
Cambridge CB2 8AH, UK. 7The School of Philosophy, Psychology, and
Language Sciences, University of Edinburgh, Dugald Stewart Building, 3
Charles Street, Edinburgh EH8 9AD, UK. 8Department of Psychiatry, Brain
Center Rudolf Magnus, University Medical Center Utrecht, Universiteitsweg
100, 3584 CG, Utrecht, The Netherlands. 9Child and Adolescent Psychiatry,
Central Institute of Mental Health, University of Heidelberg, Medical Faculty
Mannheim, J5, 68159 Mannheim, Germany. 10Donders Institute for Brain,
Cognition and Behaviour, Radboud University Nijmegen Medical Centre,
Kapittelweg 29, 6525 EN Nijmegen, The Netherlands. 11Center for
Neurodevelopmental Disorders at Karolinska Institutet (KIND), Stockholm,
Sweden. 12Child and Adolescent Psychiatry, Center of Psychiatry Research,
Stockholm County Council, Stockholm, Sweden. 13Institut Pasteur, Human
Genetics and Cognitive Functions Unit, 25 Rue du Docteur Roux, Paris Cedex
15, France. 14University Campus Bio-Medico, Via Álvaro del Portillo, 21, Rome,
Italy. 15School of Psychology and Clinical Language Sciences, University of
Reading, Whiteknights, Reading RG6 6AL, UK. 16Department of Child and
Adolescent Psychiatry, Psychosomatics and Psychotherapy, University
Hospital Frankfurt am Main, Goethe University, Deutschordenstrasse 50,
60528 Frankfurt, Germany. 17Roche Pharma Research and Early Development,
Neuroscience, Ophthalmology and Rare Diseases, Roche Innovation Center
Basel, Grenzacherstrasse 124, B.001 N.667, CH-4070 Basel, Switzerland.
18Regulatory Affairs, Pharmaceutical Development, F. Hoffmann-La Roche
Pharmaceuticals, Grenzacherstrasse 124, CH-4070 Basel, Switzerland.
19Department of Neuroscience, Uppsala University, Uppsala, Sweden.
20Centre for Brain and Cognitive Development, Birkbeck, University of
London, 32 Torrington Square, London WC1E 7JL, UK. 21Department of
Radiology, Icahn School of Medicine at Mount Sinai, NY, USA. 22Child and
Youth Mental Health Collaborative, Centre for Addiction and Mental Health
and The Hospital for Sick Children, Department of Psychiatry, University of
Toronto, 80 Workman Way, Toronto, ON M6J 1H4, Canada. 23Center for
Applied Neuroscience, Department of Psychology, University of Cyprus, PO
Box 205371678 Nicosia, Cyprus. 24Department of Psychiatry and
Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim,
University of Heidelberg, 68159 Mannheim, Germany. 25Janssen Research &
Development, 1125 Trenton Harbourton Road, Titusville, NJ 08560, USA.
26Child and Adolescent Neuropsychiatry Unit, “Gaetano Martino” University
Hospital, University of Messina, via Consolare Valeria 1, I-98125 Messina, Italy.
27Social, Genetic and Developmental Psychiatry Centre, Institute of
Psychiatry, Psychology and Neuroscience, King’s College London, Denmark
Hill, London, UK. 28Department of Child and Adolescent Psychiatry, Institute
of Psychology, Psychiatry and Neuroscience, King’s College London, De
Crespigny Park, Denmark Hill, London SE5 8LF, UK. 29Roche Pharmaceutical
Research and Early Development, NORD Discovery and Translational Area,
Roche Innovation Center Basel, Grenzacherstrasse 124, CH-4070 Basel,
Switzerland.
Received: 14 November 2016 Accepted: 19 May 2017
References
1. Baird G, Simonoff E, Pickles A, Chandler S, Loucas T, Meldrum D, Charman T.
Prevalence of disorders of the autism spectrum in a population cohort of
children in South Thames: the Special Needs and Autism Project (SNAP).
Lancet. 2006;368:210–5.
2. Brugha TS, McManus S, Bankart J, Scott F, Purdon S, Smith J, Bebbington P,
Jenkins R, Meltzer H. Epidemiology of autism spectrum disorders in adults
in the community in England. Arch Gen Psychiatry. 2011;68:459–65.
3. Christensen DL. Prevalence and characteristics of autism spectrum disorder
among children aged 8 years—autism and developmental disabilities
monitoring network, 11 sites, United States, 2012. MMWR Surveill Summ.
2016;65:1–23.
4. Gokoolparsadh A, Sutton G, A. C, Green N, Pardy C, Voineagu I. Searching
for convergent pathways in autism spectrum disorders: insights from
human brain transcriptome studies. Cell Mol Life Sci. 2016;73:4517–30.
5. American Psychiatric Association. Diagnostic and statistical manual of
mental disorders. 5th ed. Arlington: Author; 2013.
6. Lai M-C, Lombardo MV, Chakrabarti B, Baron-Cohen S. Subgrouping the
autism “spectrum”: reflections on DSM-5. PLoS Biol. 2013;11:e1001544.
7. Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G. Psychiatric
disorders in children with autism spectrum disorders: prevalence,
comorbidity, and associated factors in a population-derived sample. J Am
Acad Child Adolesc Psychiatry. 2008;47:921–9.
8. Lai M-C, Lombardo MV, Baron-Cohen S. Autism. Lancet. 2014;383:896–910.
9. Charman T. Variability in neuro-developmental disorders evidence from
autism spectrum disorders. In: Van Herwegen J, Riby DM, editors.
Neurodevelopmental Disorders : Research Challenges and Solutions. Hove:
Psychology Press; 2015.
10. Lord C, Bishop S, Anderson D. Developmental trajectories as autism
phenotypes. Am J Med Genet C: Semin Med Genet. 2015;169:198–208.
11. LLombardo MV, Lai M-C, Auyeung B, Holt RJ, Allison C, Smith P, Chakrabarti B,
Ruigrok AN, Suckling J, Bullmore ET, MRC AIMS Consortium, Ecker C, Craig MC,
Murphy DGM, Happé F, Baron-Cohen S. Unsupervised data-driven stratification
of mentalizing heterogeneity in autism. Scientific Reports. 2016;6:35333.
12. Gaugler T, Klei L, Sanders SJ, Bodea CA, Goldberg AP, Lee AB, Mahajan M,
Manaa D, Pawitan Y, Reichert J. Most genetic risk for autism resides with
common variation. Nat Genet. 2014;46:881–5.
13. Geschwind DH, State MW. Gene hunting in autism spectrum disorder: on
the path to precision medicine. Lancet Neurol. 2015;14:1109–20.
14. Bourgeron T. From the genetic architecture to synaptic plasticity in autism
spectrum disorder. Nat Rev Neurosci. 2015;16:551–63.
15. Mandy W, Lai MC. Annual research review: the role of the environment in
the developmental psychopathology of autism spectrum condition. J Child
Psychol Psychiatry. 2016;57:271–92.
16. Jeste SS, Geschwind DH. Disentangling the heterogeneity of autism
spectrum disorder through genetic findings. Nat Rev Neurol. 2014;10:74–81.
17. Zhao Y, Castellanos FX. Annual research review: discovery science
strategies in studies of the pathophysiology of child and adolescent
psychiatric disorders‐promises and limitations. J Child Psychol
Psychiatry. 2016;57:421–39.
18. Lai M-C, Lombardo MV, Auyeung B, Chakrabarti B, Baron-Cohen S. Sex/
gender differences and autism: setting the scene for future research. J Am
Acad Child Adolesc Psychiatry. 2015;54:11–24.
19. Van Wijngaarden-Cremers PJ, van Eeten E, Groen WB, Van Deurzen PA,
Oosterling IJ, Van der Gaag RJ. Gender and age differences in the core triad
of impairments in autism spectrum disorders: a systematic review and
meta-analysis. J Autism Dev Disord. 2014;44:627–35.
20. Dworzynski K, Ronald A, Bolton P, Happé F. How different are girls and boys
above and below the diagnostic threshold for autism spectrum disorders?
J Am Acad Child Adolesc Psychiatry. 2012;51:788–97.
21. Wilson CE, Murphy CM, McAlonan G, Robertson DM, Spain D, Hayward H,
Woodhouse E, Deeley PQ, Gillan N, Ohlsen JC. Does sex influence the diagnostic
evaluation of autism spectrum disorder in adults? Autism. 2016;20:808–19.
22. Frazier TW, Georgiades S, Bishop SL, Hardan AY. Behavioral and cognitive
characteristics of females and males with autism in the Simons Simplex
Collection. J Am Acad Child Adolesc Psychiatry. 2014;53:329–40. e323.
23. Szatmari P, Liu XQ, Goldberg J, Zwaigenbaum L, Paterson AD,
Woodbury‐Smith M, Georgiades S, Duku E, Thompson A. Sex differences
in repetitive stereotyped behaviors in autism: implications for genetic
liability. Am J Med Genet B Neuropsychiatr Genet. 2012;159:5–12.
24. Hiller RM, Young RL, Weber N. Sex differences in autism spectrum disorder
based on DSM-5 criteria: evidence from clinician and teacher reporting.
J Abnorm Child Psychol. 2014;42:1381–93.
25. Mandy W, Chilvers R, Chowdhury U, Salter G, Seigal A, Skuse D. Sex
differences in autism spectrum disorder: evidence from a large sample of
children and adolescents. J Autism Dev Disord. 2012;42:1304–13.
Charman et al. Molecular Autism  (2017) 8:27 Page 19 of 21
26. May T, Cornish K, Rinehart N. Does gender matter? A one year follow-up of
autistic, attention and anxiety symptoms in high-functioning children with
autism spectrum disorder. J Autism Dev Disord. 2014;44:1077–86.
27. Charman T, Taylor E, Drew A, Cockerill H, Brown J-A, Baird G. Outcome at
7 years of children diagnosed with autism at age 2: predictive validity of
assessments conducted at 2 and 3 years of age and pattern of symptom
change over time. J Child Psychol Psychiatry. 2005;46:500–13.
28. Fountain C, Winter AS, Bearman PS. Six developmental trajectories
characterize children with autism. Pediatrics. 2012;129:e1112–20.
29. Gotham K, Pickles A, Lord C. Trajectories of autism severity in children using
standardized ADOS scores. Pediatrics. 2012;130:e1278–84.
30. Lombardo MV, Pierce K, Eyler LT, Barnes CC, Ahrens-Barbeau C, Solso S,
Campbell K, Courchesne E. Different functional neural substrates for good
and poor language outcome in autism. Neuron. 2015;86:567–77.
31. Szatmari P, Georgiades S, Duku E, Bennett TA, Bryson S, Fombonne E,
Mirenda P, Roberts W, Smith IM, Vaillancourt T. Developmental trajectories
of symptom severity and adaptive functioning in an inception cohort of
preschool children with autism spectrum disorder. JAMA Psychiatry. 2015;
72:276–83.
32. Bal VH, Kim S-H, Cheong D, Lord C. Daily living skills in individuals with autism
spectrum disorder from 2 to 21 years of age. Autism. 2015;19:774–84.
33. Szatmari P, Bryson S, Duku E, Vaccarella L, Zwaigenbaum L, Bennett T, Boyle
MH. Similar developmental trajectories in autism and Asperger syndrome:
from early childhood to adolescence. J Child Psychol Psychiatry. 2009;50:
1459–67.
34. Billstedt E, Carina Gillberg I, Gillberg C. Autism in adults: symptom patterns
and early childhood predictors. Use of the DISCO in a community sample
followed from childhood. J Child Psychol Psychiatry. 2007;48:1102–10.
35. Howlin P, Moss P, Savage S, Rutter M. Social outcomes in mid-to later
adulthood among individuals diagnosed with autism and average
nonverbal IQ as children. J Am Acad Child Adolesc Psychiatry. 2013;52:
572–81. e571.
36. Shattuck PT, Seltzer MM, Greenberg JS, Orsmond GI, Bolt D, Kring S, Lounds
J, Lord C. Change in autism symptoms and maladaptive behaviors in
adolescents and adults with an autism spectrum disorder. J Autism Dev
Disord. 2007;37:1735–47.
37. Verheij C, Louwerse A, van der Ende J, Eussen M, Van Gool A, Verheij F,
Verhulst F, Greaves-Lord K. The stability of comorbid psychiatric disorders:
a 7 year follow up of children with pervasive developmental disorder-not
otherwise specified. J Autism Dev Disord. 2015;45:3939–48.
38. Simonoff E, Jones CR, Baird G, Pickles A, Happé F, Charman T. The
persistence and stability of psychiatric problems in adolescents with autism
spectrum disorders. J Child Psychol Psychiatry. 2013;54:186–94.
39. Taylor JL, Seltzer MM. Changes in the autism behavioral phenotype during
the transition to adulthood. J Autism Dev Disord. 2010;40:1431–46.
40. Lever AG, Geurts HM. Psychiatric co-occurring symptoms and disorders in
young, middle-aged, and older adults with autism spectrum disorder. J
Autism Dev Disord. 2016;46:1916–30.
41. Bishop SL, Richler J, Lord C. association between restricted and repetitive
behaviors and nonverbal IQ in children with autism spectrum disorders.
Child Neuropsychol. 2006;12:247–67.
42. Mayes SD, Calhoun SL, Murray MJ, Zahid J. Variables associated with anxiety
and depression in children with autism. J Dev Phys Disabil. 2011;23:325–37.
43. Ford T, Goodman R, Meltzer H. The relative importance of child, family,
school and neighbourhood correlates of childhood psychiatric disorder. Soc
Psychiatry Psychiatr Epidemiol. 2004;39:487–96.
44. Hinshaw SP. Externalizing behavior problems and academic
underachievement in childhood and adolescence: causal relationships and
underlying mechanisms. Psychol Bull. 1992;111:127.
45. van Steensel FJA, Bögels SM, Perrin S. Anxiety disorders in children and
adolescents with autistic spectrum disorders: a meta-analysis. Clin Child Fam
Psychol Rev. 2011;14:302.
46. Loth E, Charman T, Mason L, Jones EJH, Wooldridge C, Amad J, Auyeung B,
Brogna C, Ambrosino S, Banaschewski T, et al.. The EU-AIMS Longitudinal
European Autism Project (LEAP): design and methodologies to identify and
validate stratification biomarkers for autism spectrum disorders. Molecular
Autism (submitted).
47. Murphy D, Spooren W. EU-AIMS: a boost to autism research. Nat Rev Drug
Discov. 2012;11:815.
48. Loth E, Spooren W, Murphy DG. New treatment targets for autism spectrum
disorders: EU-AIMS. Lancet Psychiatry. 2014;1:413–5.
49. Loth E, Spooren W, Ham LM, Isaac MB, Auriche-Benichou C,
Banaschewski T, Baron-Cohen S, Broich K, Bölte S, Bourgeron T.
Identification and validation of biomarkers for autism spectrum
disorders. Nat Rev Drug Discov. 2016;15:70–3.
50. American Psychiatric Association. Diagnostic and statistical manual of
mental disorders. 4th ed. Washington, DC: Author; 1994.
51. Association AP. Diagnostic and statistical manual of mental disorders. 4th
ed. Washington, DC: American Psychiatric Association; 2000.
52. Organization WH. The ICD-10 Classification of mental and behavioural
disorders: diagnostic criteria for research. Geneva: WHO; 1993. 2013.
53. Lord C, Risi S, Lambrecht L, Cook EH, Leventhal BL, DiLavore PC, Pickles A,
Rutter M. The Autism Diagnostic Observation Schedule—Generic: a
standard measure of social and communication deficits associated with the
spectrum of autism. J Autism Dev Disord. 2000;30:205–23.
54. Lord C, Rutter M, DiLavore PC, Risi S, Gotham K, Bishop S. Autism Diagnostic
Observation Schedule, Second Edition (ADOS-2) manual (part I): modules
1–4. Torrance: Western Psychological Services; 2012.
55. Rutter M, Le Couteur A, Lord C. Autism Diagnostic Interview-Revised. Los
Angeles: Western Psychological Services; 2003.
56. Lord C, Risi S, DiLavore PS, Shulman C, Thurm A, Pickles A. Autism from 2 to
9 years of age. Arch Gen Psychiatry. 2006;63:694–701.
57. Charman T, Gotham K. Measurement issues: screening and diagnostic
instruments for autism spectrum disorders—lessons from research and
practise. Child Adolesc Mental Health. 2013;18:52–63.
58. Constantino JN, Gruber CP. Social Responsiveness Scale. 2nd ed. Los
Angeles: Western Psychological Services; 2012.
59. Anagnostou E, Jones N, Huerta M, Halladay AK, Wang P, Scahill L, Horrigan
JP, Kasari C, Lord C, Choi D. Measuring social communication behaviors as a
treatment endpoint in individuals with autism spectrum disorder. Autism.
2015;19:622–36.
60. McConachie H, Parr JR, Glod M, Hanratty J, Livingstone N, Oono IP, Robalino S,
Baird G, Beresford B, Charman T, Garland D, Green J, Gringras P, Jones G, Law J,
Le Couteur AS, Macdonald G, McColl EM, Morris C, Rodgers J, Simonoff E,
Terwee CB, Williams K. Systematic review of tools to measure outcomes for
young children with autism spectrum disorder. Health Technol Assess.
2015;41:1–506.
61. Scahill L, Hallett V, Aman MG, McDougle CJ, Arnold LE, McCracken JT,
Tierney E, Deng Y, Dziura J, Vitiello B. Brief report: Social disability in autism
spectrum disorder: Results from research units on pediatric
psychopharmacology (RUPP) autism network trials. J Autism Dev Disord.
2013;43:739–46.
62. Baron-Cohen S, Wheelwright S, Skinner R, Martin J, Clubley E. The
Autism-Spectrum Quotient (AQ): evidence from Asperger syndrome/
high-functioning autism, males and females, scientists and
mathematicians. J Autism Dev Disord. 2001;31:5–17.
63. Baron-Cohen S, Hoekstra RA, Knickmeyer R, Wheelwright S. The
autism-spectrum quotient (AQ)—adolescent version. J Autism Dev
Disord. 2006;36:343–50.
64. Auyeung B, Baron-Cohen S, Wheelwright S, Allison C. The autism spectrum
quotient: children’s version (AQ-Child). J Autism Dev Disord. 2008;38:1230–40.
65. Hartman CA, Luteijn E, Serra M, Minderaa R. Refinement of the Children’s
Social Behavior Questionnaire (CSBQ): an instrument that describes the
diverse problems seen in milder forms of PDD. J Autism Dev Disord. 2006;
36:325–42.
66. Horwitz E, Schoevers R, Ketelaars C, Kan C, van Lammeren A, Meesters Y, Spek
A, Wouters S, Teunisse J, Cuppen L. Clinical assessment of ASD in adults using
self-and other-report: psychometric properties and validity of the Adult Social
Behavior Questionnaire (ASBQ). Res Autism Spectr Disord. 2016;24:17–28.
67. Tomchek SD, Dunn W. Sensory processing in children with and without
autism: a comparative study using the short sensory profile. Am J Occup
Ther. 2007;61:190–200.
68. Bodfish JW, Symons FJ, Parker DE, Lewis MH. Varieties of repetitive behavior
in autism: comparisons to mental retardation. J Autism Dev Disord. 2000;30:
237–43.
69. Gotham K, Pickles A, Lord C. Standardizing ADOS scores for a measure of
severity in autism spectrum disorders. J Autism Dev Disord. 2009;39:693–705.
70. Hus V, Gotham K, Lord C. Standardizing ADOS domain scores: separating
severity of social affect and restricted and repetitive behaviors. J Autism Dev
Disord. 2014;44:2400–12.
71. Dunn W. The sensory profile manual. San Antonio: Psychological
Corporation; 1999.
Charman et al. Molecular Autism  (2017) 8:27 Page 20 of 21
72. Wechsler D. Wechsler Abbreviated Scale of Intelligence–Second Edition
(WASI-II). San Antonio: NCS Pearson; 2011.
73. Wechsler D. Wechsler Intelligence Scale for Children–Third Edition. San
Antonio: Psychological Corporation; 1991.
74. Wechsler D. Wechsler Intelligence Scale for Children–Fourth Edition. San
Antonio: Psychological Corporation; 2003.
75. Wechsler D. Wechsler Adult Intelligence Scale– Third Edition. San Antonio:
The Psychological Corporation; 1997.
76. Wechsler D. Wechsler Adult Intelligence Scale–Fourth Edition. San Antonio:
Pearson; 2008.
77. Sattler JM. Assessment of children (revised and updated. 3rd ed. San Diego:
Jerome M. Sattler; 1992.
78. Beck AT, Steer RA, Brown GK. Beck Depression Inventory-II. San Antonio: The
Psychological Corporation; 1996.
79. Beck JS, Beck AT, Jolly JB, Steer RA. Beck Youth Inventories. 2nd ed. San
Antonio: Harcourt Assessment; 2005.
80. Beck AT, Steer RA. Beck Anxiety Inventory Manual. San Antonio: The
Psychological Corporation Harcourt Brace & Company; 1993.
81. StataCorp. Stata statistical software: release 14. College Station:
StataCorp LP; 2015.
82. Tymms P. Effect sizes in multilevel models. In: Schagen I, Elliot K, editors. But
what does it mean? The use of effect sizes in educational research. Slough:
National Foundation for Educational Research; 2004.
83. Cohen J. A power primer. Psychol Bull. 1992;112:155.
84. Jack A, Pelphrey KA. Annual Research Review: Understudied populations
within the autism spectrum–current trends and future directions in
neuroimaging research. J Child Psychol Psychiatry. J Child Psychol
Psychiatry. 2017;58:411–35.
85. Bal VH, Lord C. Replication of standardized ADOS domain scores in the
Simons simplex collection. Autism Res. 2015;8:583–92.
86. Robinson EB, St Pourcain B, Anttila V, Kosmicki JA, Bulik-Sullivan B, Grove J,
Maller J, Samocha KE, Sanders SJ, Ripke S. Genetic risk for autism spectrum
disorders and neuropsychiatric variation in the general population. Nat
Genet. 2016;48:552–5.
87. Constantino JN, Charman T. Diagnosis of autism spectrum disorder:
reconciling the syndrome, its diverse origins, and variation in expression.
Lancet Neurol. 2016;15:279–91.
88. Costello EJ, Copeland W, Angold A. Trends in psychopathology across the
adolescent years: what changes when children become adolescents, and
when adolescents become adults? J Child Psychol Psychiatry. 2011;52:1015–25.
89. Leyfer OT, Folstein SE, Bacalman S, Davis NO, Dinh E, Morgan J, Tager-
Flusberg H, Lainhart JE. Comorbid psychiatric disorders in children with
autism: interview development and rates of disorders. J Autism Dev Disord.
2006;36:849–61.
90. Hus V, Bishop S, Gotham K, Huerta M, Lord C. Factors influencing scores on
the social responsiveness scale. J Child Psychol Psychiatry. 2013;54:216–24.
91. Mazefsky CA, Kao J, Oswald DP. Preliminary evidence suggesting caution in
the use of psychiatric self-report measures with adolescents with high-
functioning autism spectrum disorders. Res Autism Spectr Disord. 2011;5:
164–74.
92. Achenbach TM, McConaughy SH, Howell CT. Child/adolescent behavioral
and emotional problems: implications of cross-informant correlations for
situational specificity. Psychol Bull. 1987;101:213–32.
93. Baron-Cohen S, Cassidy S, Auyeung B, Allison C, Achoukhi M, Robertson S,
Pohl A, Lai M-C. Attenuation of typical sex differences in 800 adults with
autism vs. 3,900 controls. PLoS One. 2014;9:e102251.
94. Lai M-C, Lombardo MV, Pasco G, Ruigrok AN, Wheelwright SJ, Sadek SA,
Chakrabarti B, Baron-Cohen S, Consortium MA. A behavioral comparison of
male and female adults with high functioning autism spectrum conditions.
PLoS One. 2011;6:e20835.
95. Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven
pillars of RDoC. BMC Med. 2013;11:1.
96. Staal WG, de Krom M, de Jonge MV. Brief report: the dopamine-3-receptor
gene (DRD3) is associated with specific repetitive behavior in autism
spectrum disorder (ASD). J Autism Dev Disord. 2012;42:885–8.
97. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a
revised version of a diagnostic interview for caregivers of individuals with
possible pervasive developmental disorders. J Autism Dev Disord. 1994;24:
659–85.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Charman et al. Molecular Autism  (2017) 8:27 Page 21 of 21
